Combination antiretroviral therapy (ART) has transformed HIV-1 infection into a chronic condition with near-normal life expectancy. For more than two decades, the standard regimen has been a ...

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with ...

A new study in mice hints at the potential to use tiny particles made with RNA molecules to deliver chemotherapy drugs and ...

A study in Emerging Microbes & Infections reports that VV116—an oral antiviral already approved for Covid-19 treatment in China and Uzbekistan—strongly inhibited Nipah virus strains in the lab and ...

Switching to a 2-drug ART regimen was highly effective and well tolerated in virologically suppressed patients with HIV.

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...

Q4 2025 earnings call highlights: 2026 guidance, KEYTRUDA LOE risks, $70B pipeline outlook, and new launches—read now.

The Hong Kong International Airport has ramped up health screening measures amid rising Nipah virus (NiV) cases in January ...

On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...

Merck & Co., Inc. (NYSE:MRK) Q4 2025 Earnings Call Transcript February 3, 2026 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.04, expectations were $2.01. Operator: Thank you for ...

DNA polymerases carry out crucial functions in many DNA metabolic processes. Polymerases catalyse the addition, using a template, of complementary nucleotides to the 3′ end of DNA primer strands. Many ...

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk ...